Management of Hepatitis C Virus Infection in Patients With Chronic Kidney Disease: Position Statement of the Joint Committee of Italian Association for the Study of the Liver (AISF), Italian Society of Internal Medicine (SIMI), Italian Society of Infectious and Tropical Disease (SIMIT) and Italian Society of Nephrology (SIN)

J Nephrol. 2018 Oct;31(5):685-712. doi: 10.1007/s40620-018-0523-1. Epub 2018 Sep 25.


Hepatitis C virus (HCV) infection is now considered a systemic disease due to the occurrence of extra-hepatic manifestations. Among these, the renal involvement is frequent. HCV infection, in fact, is strongly associated with proteinuria and chronic kidney disease (CKD) and negatively affects the prognosis of renal patients. In the last few years, availability of more specific and effective drugs against HCV has dramatically changed the clinical course of this disease. These drugs may provide further advantages in the CKD population as a whole by reducing progression of renal disease, mortality rate and by increasing the survival of graft in renal transplant recipients. The strict pathogenetic and prognostic link between HCV infection and CKD requires an ongoing relationship among the healthcare professionals involved in the treatment of both HCV infection and CKD. Therefore, Scientific Societies involved in the care of this high-risk population in Italy have organized a joint expert panel. The aim of the panel is to produce a position statement that can be used in daily clinical practice for the management of HCV infected patients across the whole spectrum of renal disease, from the conservative phase to renal replacement treatments (dialysis and transplantation). Sharing specific evidence-based expertise of different professional healthcare is the first step to obtain a common ground of knowledge on which to instate a model for multidisciplinary management of this high-risk population. Statements cover seven areas including epidemiology of CKD, HCV-induced glomerular damage, HCV-related renal risk, staging of liver disease in patients with CKD, prevention of transmission of HCV in hemodialysis units, treatment of HCV infection and management of HCV in kidney transplantation.

Keywords: Chronic kidney disease; Direct-acting antiviral agents; HCV in renal transplantation; HCV infection.

Publication types

  • Practice Guideline

MeSH terms

  • Antiviral Agents / adverse effects
  • Antiviral Agents / therapeutic use*
  • Consensus
  • Evidence-Based Medicine
  • Hepacivirus / drug effects*
  • Hepacivirus / physiology
  • Hepatitis C, Chronic / diagnosis
  • Hepatitis C, Chronic / drug therapy*
  • Hepatitis C, Chronic / epidemiology
  • Hepatitis C, Chronic / transmission
  • Humans
  • Kidney Transplantation* / adverse effects
  • Prevalence
  • Renal Dialysis* / adverse effects
  • Renal Insufficiency, Chronic / diagnosis
  • Renal Insufficiency, Chronic / epidemiology
  • Renal Insufficiency, Chronic / therapy*
  • Risk Assessment
  • Risk Factors
  • Treatment Outcome


  • Antiviral Agents